MSD, Daiichi Sankyo’s Ifinatamab Deruxtecan Receives FDA Priority

MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority

MSD and Daiichi Sankyo have received priority review from the FDA for ifinatamab deruxtecan’s BLA to treat ES-SCLC.The post MSD, Daiichi Sankyo’s ifinatamab deruxtecan receives FDA priority appeared first on Hospital Management.

Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based Chemotherapy

Based on results from IDeate-Lung01 Phase 2 trial, with support from IDeate-PanTumor01 Phase 1/2 trial If approved, ifinatamab deruxtecan would be a first-in-class B7-H3 directed DXd antibody drug conjugate for these patients RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, Biologics License more... The post Ifinatamab Deruxtecan Granted Priority R…